SPAC combinationOct 18, 2026Pending
🇺🇸 United States
TBTriGemX Bio, Inc.TATCGX Acquisition Corp.
Healthcare › Biotechnology
Equity value$361MEquity value
AnnouncedOct 18, 2026
ConsiderationStock
StructureOne-step merger
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
TCGX Acquisition Corp. agreed to acquire TriGemX Bio, Inc. in a business combination in which TriGemX merges with a subsidiary of TCGX and TriGemX stockholders receive shares of New TriGemX Common Stock based on an agreed pre-money equity value of $361,000,000.
Deal rationale
The document presents the transaction as a business combination to take TriGemX Bio public as New TriGemX and support its migraine-focused biopharmaceutical business.
AI-generated from the SEC filingPendingHealthcare › BiotechnologyUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | $361M | Headline figure |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Stock |
Advisors
Buy-side
JJefferiesTSTD Securities
Sell-side
None listed
Parties
Target
TBTriGemX Bio, Inc.
- Headquarters
- United States
- Ticker
- —
Acquirer
TATCGX Acquisition Corp.
- Headquarters
- United States
- Ticker
- —